[go: up one dir, main page]

MX2016017348A - Metodos para tratar infecciones. - Google Patents

Metodos para tratar infecciones.

Info

Publication number
MX2016017348A
MX2016017348A MX2016017348A MX2016017348A MX2016017348A MX 2016017348 A MX2016017348 A MX 2016017348A MX 2016017348 A MX2016017348 A MX 2016017348A MX 2016017348 A MX2016017348 A MX 2016017348A MX 2016017348 A MX2016017348 A MX 2016017348A
Authority
MX
Mexico
Prior art keywords
methods
treating infections
days
treating
risk
Prior art date
Application number
MX2016017348A
Other languages
English (en)
Inventor
Longcor Jarrod
J Hopkins Scott
Li Danping
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016017348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2016017348A publication Critical patent/MX2016017348A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invencion se refiere a metodos para tratar, prevenir, o reducir el de infecciones microbianas al mismo tiempo que minimiza los efectos adversos gastrointestinales usando un regimen de dosificacion de dos etapas que comprende aproximadamente 1 hasta aproximadamente 7 dias de administracion intravenosa seguido por aproximadamente 1 hasta aproximadamente 14 dias de administracion oral de un agente antimicrobiano.
MX2016017348A 2014-06-20 2015-06-19 Metodos para tratar infecciones. MX2016017348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014790P 2014-06-20 2014-06-20
US201462034468P 2014-08-07 2014-08-07
PCT/US2015/036699 WO2015196076A1 (en) 2014-06-20 2015-06-19 Methods for treating infections

Publications (1)

Publication Number Publication Date
MX2016017348A true MX2016017348A (es) 2017-04-06

Family

ID=54868662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017348A MX2016017348A (es) 2014-06-20 2015-06-19 Metodos para tratar infecciones.

Country Status (17)

Country Link
US (2) US20150366858A1 (es)
EP (1) EP3157633A4 (es)
JP (1) JP2017518354A (es)
CN (1) CN106687179A (es)
AU (1) AU2015276911A1 (es)
BR (1) BR112016029896A2 (es)
CA (1) CA2952955A1 (es)
CL (1) CL2016003271A1 (es)
EA (1) EA201692531A1 (es)
EC (1) ECSP16095557A (es)
IL (1) IL249616A0 (es)
MX (1) MX2016017348A (es)
PH (1) PH12016502547A1 (es)
SV (1) SV2016005348A (es)
TW (1) TW201605447A (es)
UY (1) UY36183A (es)
WO (1) WO2015196076A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
EP3056492B1 (en) * 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
WO2006110815A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
CN102164912B (zh) * 2008-09-24 2015-08-19 麦林塔医疗有限公司 制备喹诺酮类化合物的工艺
WO2010056872A2 (en) * 2008-11-15 2010-05-20 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
BR112015023044A8 (pt) * 2013-03-15 2021-09-28 Melinta Subsidiary Corp Métodos para tratar infecções em pacientes acima do peso e obesos com o uso de antibióticos

Also Published As

Publication number Publication date
PH12016502547A1 (en) 2017-04-10
AU2015276911A1 (en) 2017-01-12
US20150366858A1 (en) 2015-12-24
EP3157633A1 (en) 2017-04-26
US20170368055A1 (en) 2017-12-28
CN106687179A (zh) 2017-05-17
EP3157633A4 (en) 2018-02-21
AU2015276911A2 (en) 2018-04-26
JP2017518354A (ja) 2017-07-06
EA201692531A1 (ru) 2017-05-31
CA2952955A1 (en) 2015-12-23
IL249616A0 (en) 2017-02-28
ECSP16095557A (es) 2017-03-31
TW201605447A (zh) 2016-02-16
UY36183A (es) 2016-01-29
CL2016003271A1 (es) 2017-08-04
BR112016029896A2 (pt) 2017-08-22
WO2015196076A1 (en) 2015-12-23
SV2016005348A (es) 2017-03-02

Similar Documents

Publication Publication Date Title
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NZ730809A (en) Methods for treating filoviridae virus infections
WO2016142445A3 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
MY179292A (en) Monobactam organic compounds for the treatment of bacterial infections
MY197698A (en) Oxysterols and methods of use thereof
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
PH12016502003A1 (en) Novel bacteriophage and composition containing same
EP4268897A3 (en) Minocycline compounds for biodefense
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX384724B (es) Regímenes de dosificación de melflufen para cáncer.
WO2015001541A3 (en) Pharmaceutical film composition
PH12016502568A1 (en) Novel heterocyclic compound
MY172656A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
PH12016502547A1 (en) Methods for treating infections
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
HK1232485A1 (en) Methods for treating infections
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
CR20160591A (es) Metodos para tratar infecciones
PH12016502548B1 (en) Antimicrobial compositions with effervescent agents